SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ghmm who wrote (482)4/5/2012 8:13:36 PM
From: ghmm   of 508
 
On the InterMune call to me the begin negatives were the delay in launch not only for France but also Italy and Spain to likely Q4 because of price negotiations. The other negative was the problem with Pirfenidone generics being made available in some Latin American countries based on where InterMune was trying to enroll patients ( ascendtrial.com ) and their history in the drug industry Brazil would seem to be the likely country in question. I am not concerned as much the impact it having on enrollment in ASCEND but on (potential) future sales into North America in particular. I still think the delay in enrollment may work out to InterMune's benefit in terms of reimbursement price reassement for Germany and by management comments I think they are in no hurry to rush enrollment I think this may be an unspoken reason.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News